Last reviewed · How we verify
Iloprost Injection, for intravenous use
Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, promoting vasodilation and inhibiting platelet aggregation.
Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, promoting vasodilation and inhibiting platelet aggregation. Used for Pulmonary arterial hypertension, Raynaud's phenomenon secondary to systemic sclerosis.
At a glance
| Generic name | Iloprost Injection, for intravenous use |
|---|---|
| Sponsor | Civi Biopharma, Inc. |
| Drug class | Prostacyclin analog |
| Target | Prostacyclin receptor (IP receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Iloprost mimics the action of prostacyclin (PGI2), a naturally occurring eicosanoid that regulates vascular tone and platelet function. By activating prostacyclin receptors, it causes direct vasodilation of pulmonary and systemic vasculature and reduces platelet activation and aggregation. This mechanism makes it effective in conditions characterized by pulmonary hypertension and peripheral vascular dysfunction.
Approved indications
- Pulmonary arterial hypertension
- Raynaud's phenomenon secondary to systemic sclerosis
Common side effects
- Flushing
- Headache
- Hypotension
- Jaw pain
- Nausea
- Diarrhea
Key clinical trials
- Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) (PHASE2)
- Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iloprost Injection, for intravenous use CI brief — competitive landscape report
- Iloprost Injection, for intravenous use updates RSS · CI watch RSS
- Civi Biopharma, Inc. portfolio CI